Efficacy of Vitamin B1 in Familial Adenomatous Polyposis Patients. (NCT06649825) | Clinical Trial Compass
By InvitationNot Applicable
Efficacy of Vitamin B1 in Familial Adenomatous Polyposis Patients.
China10 participantsStarted 2024-01-08
Plain-language summary
This study aimed to investigate the efficacy of vitamin B1 in patients with familial adenomatous polyposis, and to determine the inhibitory effect of vitamin B1 on the size and number of colorectal adenomas by administering oral vitamin B1 therapy for 1 year and colonoscopy follow-up every 3 months
Who can participate
Age range18 Years β 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
β. Patients with a confirmed diagnosis of classical familial adenomatous polyposis (FAP) based on colonoscopy, histopathology, and genetic testing.
β. Aged between 18 and 80 years, with no restriction on gender.
β. No history of total colectomy, with remaining bowel segments available for evaluation.
β. Presence of more than 10 adenomatous polyps in the colon or rectum.
β. Normal liver and kidney function.
β. Willing to participate in vitamin B1 therapy and commit to regular follow-up appointments.
Exclusion criteria
β. Use of medications for more than one week in the past three months, or inability to avoid continuous use during the study period, that may affect colorectal polyps, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), Ο-3 polyunsaturated fatty acids, rapamycin, and curcumin.
β. Use of medications for more than one week in the past three months, or inability to avoid continuous use during the study period, that may affect vitamin B1 absorption, metabolism, or excretion, including aminoglycoside antibiotics, thiazide diuretics, oral contraceptives, antiepileptic drugs, and antituberculosis drugs.